“…Nanoparticle vaccines include assemblies of synthesized polypeptides, presenting multiple copies of subunit antigens that can potentially mimic the size and shape of the natural antigenic virus‐encoded proteins. Phase I, II, and III clinical trials on RSV F nanoparticle vaccines, with or without adjuvants, are ongoing in adults, including healthy third‐trimester pregnant women . - Subunit vaccines, based on purified proteins isolated from RSV that have an elevated capacity to induce neutralizing antibodies, are in different phase clinical trials . These include the purified F protein, the central conserved region of the RSV‐A G protein, a chimeric RSV F‐G fusion protein, the CX3C central conserved region of the G protein, a post‐fusion RSV F protein formulated with a synthetic TLR4 agonist, purified recombinant pre‐fusion F protein, and extracellular domain of the SH protein .
- Live‐attenuated RSV vaccines must be characterized by a sufficiently attenuated viral replication to be safe in RSV‐naive infants but not too attenuated to eliminate an effective immune response with an adequate balance between safety and efficacy.
…”